Genetic deletion or pharmacologic inhibition of histone deacetylase 6 protects the heart against ischaemia/reperfusion injury by limiting tumour necrosis factor alpha–induced mitochondrial injury in experimental diabetes
Cardiovascular Research

Abstract
The histone deacetylase 6 (HDAC6) inhibitor, tubastatin A (TubA), reduces myocardial ischaemia/reperfusion injury (MIRI) in type 1 diabetic rats. It remains unclear whether HDAC6 regulates MIRI in type 2 diabetic animals. Diabetes augments the activity of HDAC6 and the generation of tumour necrosis factor alpha (TNF-α) and impairs mitochondrial complex I (mCI). Here, we examined how HDAC6 regulates TNF-α production, mCI activity, mitochondria, and cardiac function in type 1 and type 2 diabetic mice undergoing MIRI.
HDAC6 knockout, streptozotocin-induced type 1 diabetic, and obese type 2 diabetic db/db mice underwent MIRI
HDAC6 is an essential negative regulator of MIRI in diabetes. Genetic deletion or pharmacologic inhibition of HDAC6 protects the heart from MIRI by limiting TNF-α–induced mitochondrial injury in experimental diabetes.
Contributors

Shelley L Baumgardt
Author

Juan Fang
Author

Xuebin Fu
Author

Yanan Liu
Author

Zhengyuan Xia
Author

Ming Zhao
Author

Ling Chen
Author

Rachana Mishra
Author

Muthukumar Gunasekaran
Author

Progyaparamita Saha
Author

Joseph M Forbess
Author

Zeljko J Bosnjak
Author

Amadou K S Camara
Author

Judy R Kersten
Author

Edward B Thorp
Author

Sunjay Kaushal
Author

Zhi-Dong Ge
Author
You may be interested in


